美国类风湿学会/欧洲防治风湿病联盟:2010类风湿性关节炎分类标准

美国类风湿学会/欧洲防治风湿病联盟:2010类风湿性关节炎分类标准

类风湿性关节炎又称类风湿(RA),是一种伴急性发作的慢性多发性关节病变,结缔组织病的一种。 继续阅读“美国类风湿学会/欧洲防治风湿病联盟:2010类风湿性关节炎分类标准”

新美国居民膳食指南继续强调减低食盐摄入量

期待已久的美国居民膳食指南周一得以公布,该指南将继续督促美国居民降低食盐的摄入。

期待已久的美国居民膳食指南周一得以公布,该指南将继续督促美国居民降低食盐的摄入。 继续阅读“新美国居民膳食指南继续强调减低食盐摄入量”

美国心脏协会和美国卒中协会发布新卒中治疗指南

美国心脏协会和美国卒中协会制定新卒中治疗指南,该指南将会出现在Stroke(卒中)期刊。

使脑卒中患者得到更快的诊断和治疗是美国心脏协会和美国卒中协会制定新指南的基石。 继续阅读“美国心脏协会和美国卒中协会发布新卒中治疗指南”

美国传染病协会发布耐甲氧西林金黄色葡萄球菌感染治疗指南

耐甲氧西林金黄色葡萄球菌(MRSA)是医院内感染和社区感染中常见的致病原,致病力强而治疗效果差,美国传染病协会(The Infectious Diseases Society of America , IDSA)近期在《临床传染病》杂志发布了MRSA治疗指南。

近期,美国传染病协会(The Infectious Diseases Society of America , IDSA)发布了第一个全国性耐甲氧西林金黄色葡萄球菌(MRSA)治疗指南。 继续阅读“美国传染病协会发布耐甲氧西林金黄色葡萄球菌感染治疗指南”

美国泌尿外科医师协会早泄诊疗指南(AUA Premature Ejaculation Clinical Guidelines)

早泄(premature ejaculation,PE)是一种常见的男性性功能障碍,影响20%-30%的成年男性,目前对其产生机制尚不完全了解。甚至到目前为止,尚没有一个能被普遍接受的定义。

早泄(premature ejaculation,PE)是一种常见的男性性功能障碍,影响20%-30%的成年男性,目前对其产生机制尚不完全了解。甚至到目前为止,尚没有一个能被普遍接受的定义。 继续阅读“美国泌尿外科医师协会早泄诊疗指南(AUA Premature Ejaculation Clinical Guidelines)”

高血压防治指南

高血压是一种古老的疾病,一百多年前 Riva-Rocci 发明了袖带血压计后医学界才对高血压的生理和病理意义有了认识。20 世纪 50-60 年代开展了大量人群血压分布及血压与心血管病关系的流行病学和临床研究,证实了高血压是引起心血管病的主要危险因素。

高血压是一种古老的疾病,一百多年前 Riva-Rocci 发明了袖带血压计后医学界才对高血压的生理和病理意义有了认识。20 世纪 50-60 年代开展了大量人群血压分布及血压与心血管病关系的流行病学和临床研究,证实了高血压是引起心血管病的主要危险因素。 继续阅读“高血压防治指南”

欧洲泌尿外科协会(EAU)发布2010年版ED及PE诊疗指南

EAU近日在其官方网站发布最新版的勃起功能障碍(Erectile dysfuntion)和早泄(Premature ejaculation)的诊疗指南。新版的诊疗指南和2008年版本相比,没有太大的变化,ED的一线药物仍然为PDE5抑制剂:sildenafil(西地那非), tadalafil(他达拉非)和 vardenafil(伐地那非)。欧洲泌尿外科协会官方网站可下载该指南的免费全文

EAU近日在其官方网站发布最新版的勃起功能障碍(Erectile dysfuntion)和早泄(Premature ejaculation)的诊疗指南。新版的诊疗指南和2008年版本相比,没有太大的变化,ED的一线药物仍然为PDE5抑制剂:sildenafil(西地那非), tadalafil(他达拉非)和 vardenafil(伐地那非)。

CONTEXT: Erectile dysfunction (ED) and premature ejaculation (PE) are the two most prevalent male sexual dysfunctions. OBJECTIVE: To present the updated version of 2009 European Association of Urology (EAU) guidelines on ED and PE. EVIDENCE ACQUISITION: A systematic review of the recent literature on the epidemiology, diagnosis, and treatment of ED and PE was performed. Levels of evidence and grades of recommendation were assigned. EVIDENCE SYNTHESIS: ED is highly prevalent, and 5-20% of men have moderate to severe ED. ED shares common risk factors with cardiovascular disease. Diagnosis is based on medical and sexual history, including validated questionnaires. Physical examination and laboratory testing must be tailored to the patient’s complaints and risk factors. Treatment is based on phosphodiesterase type 5 inhibitors (PDE5-Is), including sildenafil, tadalafil, and vardenafil. PDE5-Is have high efficacy and safety rates, even in difficult-to-treat populations such as patients with diabetes mellitus. Treatment options for patients who do not respond to PDE5-Is or for whom PDE5-Is are contraindicated include intracavernous injections, intraurethral alprostadil, vacuum constriction devices, or implantation of a penile prosthesis. PE has prevalence rates of 20-30%. PE may be classified as lifelong (primary) or acquired (secondary). Diagnosis is based on medical and sexual history assessing intravaginal ejaculatory latency time, perceived control, distress, and interpersonal difficulty related to the ejaculatory dysfunction. Physical examination and laboratory testing may be needed in selected patients only. Pharmacotherapy is the basis of treatment in lifelong PE, including daily dosing of selective serotonin reuptake inhibitors and topical anaesthetics. Dapoxetine is the only drug approved for the on-demand treatment of PE in Europe. Behavioural techniques may be efficacious as a monotherapy or in combination with pharmacotherapy. Recurrence is likely to occur after treatment withdrawal. CONCLUSIONS: These EAU guidelines summarise the present information on ED and PE. The extended version of the guidelines is available at the EAU Web site

欧洲泌尿外科协会官方网站可下载该指南的免费全文,下载地址 :http://www.uroweb.org/nc/professional-resources/guidelines/online